EP-1763: Acute toxicity and in-vivo dosimetry of a two week hypofractionated schedule within the HYPORT study

Achintya Saha(University of Calcutta), Soumik Chatterjee, Suvro Sankha Datta(Tata Medical Center), Garima Goswami, Saumendra Mohan Ray, Rehab Allah Ahmed, Divya Midha(Tata Medical Center), Subir Sinha(Tata Medical Center), J. Das, S. Mandal(Bose Institute), A. Mahata(Tata Medical Center), S Agarwal
Radiotherapy and Oncology
May 1, 2017
10.1016/s0167-8140(17)32126-6
Cited by 1

Related Papers

Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient data
|Gynecologic Oncology|2019|121
HYPORT adjuvant acute toxicity and patient dosimetry quality assurance results – Interim analysis
|Radiotherapy and Oncology|2022|42
ABO, Rhesus, and Kell Antigens, Alleles, and Haplotypes in West Bengal, India
|Transfusion Medicine and Hemotherapy|2017|32
Resource requirements and reduction in cardiac mortality from deep inspiration breath hold (DIBH) radiation therapy for left sided breast cancer patients: A prospective service development analysis
|Practical Radiation Oncology|2018|32
Hypofractionated radiation therapy comparing a standard radiotherapy schedule (over 3 weeks) with a novel 1-week schedule in adjuvant breast cancer: an open-label randomized controlled study (HYPORT-Adjuvant)—study protocol for a multicentre, randomized phase III trial
|Trials|2020|29